



XPERTBIOFILM: A DYNAMIC PLATFORM FOR CLINICALLY RELEVANT BIOFILM DIAGNOSTICS



CHALLENGE

The rise of **antibiotic-resistant bacteria**, combined with the lack of new antimicrobials, is a growing global threat. This is especially critical for **biofilm-associated infections**, which are intrinsically more resistant to treatments than freely growing bacteria (planktonic), making them difficult to treat and a **major clinical burden**.

However, **susceptibility testing** (antibiogram) rely on planktonic bacteria, despite known differences with biofilm-associated resistance. Current biofilm methods require confocal microscopy and specialized expertise, limiting their routine use and underscoring the need for accessible, clinically relevant **biofilm-testing tools** in standard microbiology laboratories.



MARKET

Biofilms contribute to up to 80% of chronic infections, including those in wounds, lungs, and medical devices, representing a major unmet clinical need. The global anti-biofilm market is expected to grow **from \$1.77B in 2026 to \$3.81B by 2035 (CAGR of ~8.85%)**.



ASSET

XpertBiofilm will be a breakthrough for hospital microbiology laboratories, providing a simple, standardized method for growing biofilms and performing antimicrobial susceptibility **testing directly from patient samples**.


This enables personalized treatment **decisions based on biofilm-specific susceptibility data**. By enabling routine testing of biofilm-associated bacteria, XpertBiofilm will **improve treatment efficacy**, helping reduce the development of antibiotic resistance.

Stage of Development: TLR3

Validated with **clinical strains** and direct **sputum samples** from **cystic fibrosis** patients

Asset Value

- Reduces empirical **antibiotic use**
- Improves treatment in **chronic infections**
- Enables **personalized** patient treatment plans for patients
- Enables easy antibiofilm **drug discovery**



Team



Eduard Torrents
Scientific Leader



Núria Blanco-Cabra
Researcher



Zoi Melissari
Tech Transfer



Eduardo Salas
Head of Tech Transfer

Intellectual Property

PCT was filed in April 2026
Patent Owners: IBEC, UB

Exploitation Plan

Product available for co-development and licensing.

Potentially interested parties:

- New antibiotic drug discovery programmes.
- IVD technologies for antimicrobial susceptibility testing.
- Hospitals to improve diagnostics and personalised treatments.